



June 21, 2012

Integra LifeSciences Announces Contract With aap Implantate AG to Provide Stainless Headed Compression Screws for Mid and Hindfoot Reconstruction

PLAINSBORO, N.J. and BERLIN, June 21, 2012 (GLOBE NEWSWIRE) -- [Integra LifeSciences Holdings Corporation](#) (Nasdaq:IART) today announced that it will feature its new Stainless Headed Compression Screw System, manufactured by aap Implantate AG (XETRA:AAQ), at the upcoming Orthopedic Foot and Ankle Society 2012 Annual Meeting on June 20-23, 2012 in San Diego, California.

Headed compression screws are used in orthopedics for internal fixation of bone, typically after fractures. This new system will provide a comprehensive solution for arthrodesis and fracture management across multiple disease states, including midfoot, ankle and hindfoot arthritis. The new stainless steel system will feature a midfoot set composed of 4.0mm and 4.5mm diameter screws, and a hindfoot set composed of 6.5mm and 7.5mm diameter screws. All screw diameters will be available in both partially threaded and fully threaded options.

Integra LifeSciences will distribute a private label version of the aap Implantate AG stainless headed compression screw system. aap Implantate AG is a medical device company that develops, manufactures and markets innovative biomaterials and implants that are used in orthopedic procedures.

"Headed compression screws were one of the product gaps identified by the sales force and surgeon customers, and this new product will close the gap," said Bill Weber, Vice President and General Manager, Integra Extremity Reconstruction. "We are pleased that aap Implantate AG has shown such confidence in Integra by selecting us as their contract partner for stainless headed compression screws."

Biense Visser, Chief Executive Officer of aap Implantate AG, said, "We have great respect for the team at Integra and are pleased to be providing them with a comprehensive Stainless Headed Compression Screw system. Integra has a strong reputation and proven track-record in the industry and we believe they will be an effective partner for the distribution of this product line. The partnership also provides further validation of aap's products and technology as we continue to expand our presence in markets outside of Europe, particularly in the United States."

The Integra Stainless Headed Compression Screw System will be sold by Integra's Extremity Reconstruction sales organization, which focuses on lower extremity fixation, upper extremity fixation, tendon protection, peripheral nerve repair/protection and wound repair.

About Integra LifeSciences

Integra LifeSciences, a world leader in medical devices, is dedicated to limiting uncertainty for surgeons, so they can concentrate on providing the best patient care. Integra offers innovative solutions in orthopedics, neurosurgery, spine, reconstructive and general surgery. For more information, please visit www.integralife.com.

About aap Implantate AG

aap is a global medical device company headquartered in Berlin, Germany that develops, manufactures and markets innovative biomaterials and implants that are used in orthopedic procedures. The Company's products, which include a full line of plating systems, cannulated screws and bone cement products, are primarily used in the orthopedic specialty areas of trauma and spine repair. The Company's products are sold through its direct sales force, distribution partners and license agreements with OEM partners. aap's stock is listed in the Prime Standard segment of the Frankfurt Stock Exchange. For more information, please visit www.aap.de.

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the products and services provided by Integra. Such forward looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of surgical professionals to use Integra products may affect the prospects for their use in surgical procedures. In addition, the economic, competitive, governmental, technological and other factors, identified under the heading "Risk Factors" included in Item 1A of Integra's Annual Report on Form 10-K for the year ended December 31, 2011 and information contained in subsequent filings with the Securities and Exchange Commission

could affect actual results.

CONTACT: Integra LifeSciences Holdings Corporation

Gianna Sabella

Director, Corporate Communications

(609) 936-2389

gianna.sabella@integralife.com

aap Implantate AG

Investor / Media Contact Information:

Zack Kubow / Lisa Cook

The Ruth Group

646-536-7020 / 7012

zkubow@theruthgroup.com

lcook@theruthgroup.com